ACCME Comments for FDA Public Advisory Committee Meeting on REMS, May 2016

Publish Date

The ACCME submitted these comments for the FDA public advisory committee meeting on the Extended-Release and Long-Acting (ER/LA) Opioid Analgesics REMS, May 3–4, 2016. In the comments, Graham McMahon, MD, MMSc, President and CEO, ACCME, writes: “We appreciate the FDA’s recognition of the value of accredited continuing education (CE) in carrying out this critical public health initiative. We believe that accredited CE has made — and can continue to make — significant contributions to addressing the patient safety issues identified in the ER/LA Opioid Analgesics REMS. We value our engagement with the FDA and look forward to continuing to work together to make a difference to patients, families, and communities across the country.”  

For more information, visit CME in support of REMS.